Connect with us
  • Elysium

Dementia news

Current trends and the renaissance of Alzheimer’s drug development



Rafaat Rahmani, CEO of Lifescience Dynamics, discusses current trends in drugs approval and why a resurgence is being seen in provision for Alzheimer's 

Historically, market authorisations for neurological diseases have had significantly lower rates of success than other indications.

Between 2000 to 2015, the likelihood of approval for neurological drugs (8.4 per cent) was below the mean across all indications (9.6 per cent) and far below haematology (26.1 per cent) and infectious diseases (19.1 per cent).

Read this and more exclusive content every day as an NR Times online subscriber. Just £2.99 a month, cancel anytime.

Login Join Now